Management of Urine with High Erythrocytes and Leukocytes

Initial Diagnostic Approach

The American College of Physicians recommends verifying microscopic hematuria with ≥3 red blood cells per high-power field (RBC/HPF) on properly collected clean-catch midstream urine specimens, as dipstick testing alone has limited specificity (65-99%) and should never be relied upon without microscopic confirmation 2, 3
The American Urological Association suggests obtaining urine culture immediately if infection is suspected based on the presence of leukocyturia, before initiating any antibiotic therapy 1, 4
Repeat urinalysis 6 weeks after completing antibiotic treatment to confirm resolution of hematuria, as approximately 3% of patients with microscopic hematuria harbor genitourinary malignancy 1
Rule out menstruation, vigorous exercise, sexual activity, trauma, or viral illness as potential benign causes of hematuria, and repeat urinalysis 48 hours after cessation of the potential cause 2, 1

The American Urological Association recommends stratifying patients into high-risk, intermediate-risk, and low-risk categories based on age, smoking history, and degree of hematuria, with high-risk features including age ≥60 years, smoking history >30 pack-years, and >25 RBCs per high-power field 3, 1
High-risk patients require immediate complete urologic evaluation, including multiphasic CT urography and cystoscopy, to detect renal cell carcinoma, transitional cell carcinoma, and other upper tract abnormalities 3, 1, 4

The National Kidney Foundation suggests assessing for signs of glomerular disease, including significant proteinuria >500-1000 mg/24 hours, dysmorphic RBCs >80% on microscopic examination, and red blood cell casts, which are pathognomonic for glomerular disease 3, 1, 4
Patients with glomerular disease require nephrology referral, while those with non-glomerular sources require complete urologic evaluation 3, 1, 4

The American Urological Association recommends multiphasic CT urography as the preferred imaging modality to detect renal cell carcinoma, transitional cell carcinoma, and upper tract abnormalities 3, 1, 4
Cystoscopy is mandatory for all high-risk patients and intermediate-risk patients to visualize bladder mucosa, urethra, and ureteral orifices for transitional cell carcinoma 3, 1, 4

The American Urological Association suggests repeating urinalysis at 6, 12, 24, and 36 months with blood pressure monitoring at each visit, and considering repeat complete evaluation within 3-5 years for persistent or recurrent hematuria 1, 4
Immediate re-evaluation is warranted if gross hematuria develops, significant increase in degree of microscopic hematuria occurs, new urologic symptoms appear, or development of hypertension, proteinuria, or evidence of glomerular bleeding is noted 1, 4

The American College of Physicians recommends never attributing hematuria solely to anticoagulation or antiplatelet therapy, as these medications may unmask underlying pathology but do not cause hematuria themselves 2, 3, 4
Never ignore gross hematuria, even if self-limited, as it carries a 30-40% risk of malignancy and requires urgent urologic referral 2, 1, 4